Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02762877 · ADVERSE EVENTS

Adverse events

Concordance of Key Actionable Genomic Alterations as Assessed in Tumor Tissue and Plasma in Non Small Cell Lung Cancer · Source last updated 2020-11-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame
Not reported
Other-event reporting threshold
0%

All-Cause Mortality, Serious, and Other (Not Including Serious) Adverse Events were not monitored/assessed.

Participants affected / participants at risk, as reported
Safety groupSerious eventsOther eventsDeaths
A - NSCLC All Comers Regardless of Genomic Alteration Status

Patients with non-squamous NSCLC regardless of genomic alteration status (newly diagnosed or progressing on therapy)

0 / 00 / 00 / 0
B - Progressing on EGFR Targeted Therapies

Patients with non-squamous NSCLC progressing on erlotinib, gefitinib, or afatinib

0 / 00 / 00 / 0

Group identifiers: EG000: A - NSCLC All Comers Regardless of Genomic Alteration Status · EG001: B - Progressing on EGFR Targeted Therapies

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

    Other reported adverse events

    Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

      Complete source fields
      description
      All-Cause Mortality, Serious, and Other (Not Including Serious) Adverse Events were not monitored/assessed.
      event Groups
      1. deaths Num Affected
        0
        deaths Num At Risk
        0
        description
        Patients with non-squamous NSCLC regardless of genomic alteration status (newly diagnosed or progressing on therapy)
        id
        EG000
        other Num Affected
        0
        other Num At Risk
        0
        serious Num Affected
        0
        serious Num At Risk
        0
        title
        A - NSCLC All Comers Regardless of Genomic Alteration Status
      2. deaths Num Affected
        0
        deaths Num At Risk
        0
        description
        Patients with non-squamous NSCLC progressing on erlotinib, gefitinib, or afatinib
        id
        EG001
        other Num Affected
        0
        other Num At Risk
        0
        serious Num Affected
        0
        serious Num At Risk
        0
        title
        B - Progressing on EGFR Targeted Therapies
      frequency Threshold
      0

      Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

      Preserved source evidence · Not medical advice